News
VIR
13.65
+11.75%
1.44
Vir Biotechnology (VIR) Posts Positive Phase 3 HDV Data With Durable Follow Through
Simply Wall St · 14h ago
Vir Biotechnology, Inc. Reports 44% Response Rate in Phase 3 ECLIPSE 1 Trial and Week 96 SOLSTICE Data
NASDAQ · 15h ago
Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain
NASDAQ · 15h ago
Vir Biotechnology Price Target Maintained With a $22.00/Share by HC Wainwright & Co.
Dow Jones · 18h ago
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $22 Price Target
Benzinga · 18h ago
Vir Biotech Highlights Significant Viral Suppression in Advanced Liver Disease Study
Benzinga · 20h ago
Vir Biotechnology shares rise on hepatitis D therapy data
Seeking Alpha · 20h ago
Vir Biotechnology Reports Positive Phase 3 Hepatitis Delta Trial Results
TipRanks · 21h ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 23h ago
AM Need to Know: Nvidia spy probe, Alphabet bets and more
Seeking Alpha · 23h ago
Vir Biotechnology Stock Gains on Positive Trial Results for Chronic Hepatitis Treatment
Dow Jones · 23h ago
Weekly Report: what happened at VIR last week (1102-1106)?
Weekly Report · 1d ago
Biggest stock movers Monday: NVDA, VIR, and more
Seeking Alpha · 1d ago
Vir's Hepatitis Delta Combo Shows Sustained Viral Suppression; Shares Rise 15% Premarket
NASDAQ · 1d ago
Why Greenfire Resources Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Benzinga · 1d ago
Reported Sunday, Vir’s Elebsiran And Tobevibart Meet Primary Endpoint In Phase 3 ECLIPSE 1 Hepatitis Delta Trial, 44% Achieve Undetectable Virus Plus ALT Normalization Versus 0% Delayed Treatment
Benzinga · 1d ago
Vir Biotechnology reports positive hepatitis results, early signs of possible cure
Seeking Alpha · 1d ago
Vir Biotechnology announces new, expanded data from Phase 2 Solstice trial
TipRanks · 1d ago
Vir Biotechnology announces Phase 3 Eclipse 1 trial met primary endpoint
TipRanks · 1d ago
Vir Biotechnology price target raised to $17 from $15 at BofA
TipRanks · 3d ago
More
Webull provides a variety of real-time VIR stock news. You can receive the latest news about Vir Biotechnology, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VIR
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. Its portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers (TCEs) across validated targets in solid tumor indications. It also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Its key product candidates include Elebsiran (VIR-2218); Tobevibart (VIR-3434); VIR-5818; VIR-5525, and VIR-5500. These molecules leverage the PRO-XTEN masking technology with TCEs targeting CD3 on T-cells and HER2, PSMA and EGFR, respectively, on tumor cells. Elebsiran is an investigational hepatitis B virus (HBV)-targeted small interfering RNA that reduces hepatitis B surface antigen (HBsAg). Tobevibart is an investigational neutralizing monoclonal antibody that has been engineered for immune engagement and targets a conserved region on the HBsAg.